Prevention of Cardiovascular Disease and Mortality in Patients With Psoriasis or Psoriatic Arthritis (CP3)
Status
Conditions
Treatments
Details and patient eligibility
About
The goal of this research is to test a novel centralized care coordinator program to assist patients with psoriatic disease in lowering their risk of cardiovascular disease through the application of standard of care approaches to improving modifiable cardiovascular risk factors.
Full description
Psoriasis patients have an increased risk of cardiovascular disease and mortality but are less likely to have traditional cardiovascular risk factors identified or adequately managed. Care coordinators have previously been demonstrated to improve outcomes in patients with chronic diseases (such as comorbid diabetes and depression) and are now routinely embedded in primary care practices in integrated health systems. The goal of this research is to test a novel centralized care coordinator program to assist patients with psoriatic disease in lowering their risk of cardiovascular disease through the application of standard of care approaches to improving modifiable cardiovascular risk factors.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Willing and able to provide informed consent
- Male or female aged 40-75
- Being seen by a dermatology provider in routine care for the primary encounter diagnosis of psoriasis
Exclusion criteria
- Currently taking a prescription lipid lowering medication
- Pregnant or planning pregnancy in the next 6 months
- Has a known history of cardiovascular disease (MI, Stroke, coronary artery, cerebrovascular, or peripheral vascular disease)
Trial design
Primary purpose
Allocation
Interventional model
Masking
520 participants in 1 patient group
Trial contacts and locations
Loading...
Central trial contact
Brooke Bishop, MPH
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal